Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...

Blackstone, BlackRock, and Novo Nordisk A/S are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies that are expected to grow ...

Blackstone, BlackRock, Apollo Global Management, Novo Nordisk A/S, Welltower, Prologis, and Venture Global are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool.

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

NEW YORK, NY / ACCESS Newswire / March 8, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...